Drugs / CD3/CD28 activated autologous lymphocytes
CD3/CD28 activated autologous lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01426828 | Aug 2011 → Jun 2016 | plasma cell myeloma | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD3/CD28 activated autologous lymphocytes | “CD3/CD28 activated autologous lymphocytes intravenously” NCT01426828 ↗ |
| Modality | Cell therapy | “autologous T-cell transfer” PMID 34521108 ↗ Mar 2022 |
| Route | Intravenous | “CD3/CD28 activated autologous lymphocytes intravenously” NCT01426828 ↗ |